title: Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.
abstract: BACKGROUND
  An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD). Whether the response to inhaled corticosteroids is related to the presence of eosinophilic inflammation is unclear.
  
  
  METHODS
  A randomised, double blind, crossover trial of placebo and mometasone furoate (800 microg/day), each given for 6 weeks with a 4 week washout period, was performed in subjects with COPD treated with bronchodilator therapy only. Spirometric tests, symptom scores, chronic respiratory disease questionnaire (CRQ), and induced sputum were performed before and after each treatment phase.
  
  
  RESULTS
  Ninety five patients were recruited of which 60 were randomised. Overall there were no treatment associated changes in forced expiratory volume in 1 second (FEV(1)), total CRQ, or sputum characteristics. After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV(1) increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile. The mean change in post-bronchodilator FEV(1) with mometasone compared with placebo in the highest tertile was 0.11 l (95% CI 0.03 to 0.19). This improvement was not associated with a fall in the sputum eosinophil count.
  
  
  CONCLUSIONS
  An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV(1) following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count.
authors.affiliation: Institute for Lung Health, Clinical Sciences Wing, University Hospitals of Leicester, Groby Road, Leicester LE3 9QP, UK. ceb17@le.ac.uk
authors.forename: C E
authors.initials: CE
authors.lastname: Brightling
authors.forename: S
authors.initials: S
authors.lastname: McKenna
authors.forename: B
authors.initials: B
authors.lastname: Hargadon
authors.forename: S
authors.initials: S
authors.lastname: Birring
authors.forename: R
authors.initials: R
authors.lastname: Green
authors.forename: R
authors.initials: R
authors.lastname: Siva
authors.forename: M
authors.initials: M
authors.lastname: Berry
authors.forename: D
authors.initials: D
authors.lastname: Parker
authors.forename: W
authors.initials: W
authors.lastname: Monteiro
authors.forename: I D
authors.initials: ID
authors.lastname: Pavord
authors.forename: P
authors.initials: P
authors.lastname: Bradding
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D004802:Eosinophilia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004804:Eosinophils / Q000737:chemistry; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis; D007958:Leukocyte Count; D008297:Male; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage*; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D013183:Sputum / Q000166:cytology*
chemical_list: D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D016209:Interleukin-8; D011244:Pregnadienediols; D000068656:Mometasone Furoate
references.citation: Thorax. 2003 Aug;58(8):654-8
references.pmid: 12885977
references.citation: Eur Respir J. 2003 Jan;21(1):74-81
references.pmid: 12570112
references.citation: Eur Respir J. 2003 Jan;21(1):68-73
references.pmid: 12570111
references.citation: Lancet. 2002 Nov 30;360(9347):1715-21
references.pmid: 12480423
references.citation: Eur Respir J. 2002 Oct;20(4):819-25
references.pmid: 12412670
references.citation: Am J Respir Crit Care Med. 2002 Oct 15;166(8):1084-91
references.pmid: 12379552
references.citation: Eur Respir J. 2002 Aug;20(2):325-31
references.pmid: 12212963
references.citation: Thorax. 2002 Sep;57(9):799-803
references.pmid: 12200525
references.citation: Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
references.pmid: 11316667
references.citation: Respir Med. 2001 Feb;95(2):115-21
references.pmid: 11217907
references.citation: Lancet. 2000 Oct 28;356(9240):1480-5
references.pmid: 11081531
references.citation: Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):878-82
references.pmid: 10988099
references.citation: BMJ. 2000 May 13;320(7245):1297-303
references.pmid: 10807619
references.citation: Respiration. 2000;67(1):71-6
references.pmid: 10705266
references.citation: Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635-9
references.pmid: 10556133
references.citation: Am J Respir Crit Care Med. 1999 Aug;160(2):406-10
references.pmid: 10430705
references.citation: Lancet. 1999 Jun 26;353(9171):2213-4
references.pmid: 10392993
references.citation: N Engl J Med. 1999 Jun 24;340(25):1948-53
references.pmid: 10379018
references.citation: Lancet. 1999 May 29;353(9167):1819-23
references.pmid: 10359405
references.citation: Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1511-7
references.pmid: 9817701
references.citation: Lancet. 2003 Sep 27;362(9389):1053-61
references.pmid: 14522537
references.citation: Am J Respir Crit Care Med. 2003 Dec 15;168(12):1488-94
references.pmid: 14525798
references.citation: Thorax. 2004 Feb;59(2):179; author reply 179
references.pmid: 14760166
references.citation: Thorax. 1987 Oct;42(10):773-8
references.pmid: 3321537
references.citation: Thorax. 1987 Jul;42(7):487-90
references.pmid: 3438892
references.citation: Am J Respir Crit Care Med. 1997 Feb;155(2):449-53
references.pmid: 9032177
references.citation: Am J Respir Crit Care Med. 1997 Feb;155(2):542-8
references.pmid: 9032192
references.citation: Thorax. 1998 Jul;53(7):583-5
references.pmid: 9797758